Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Pfizer Inc (NYSE:PFE) announced that an interim futility analysis of the global Phase 3 trial, REALM-DCM of PF-07265803, indicated the trial is unlikely to meet its primary endpoint upon completion.
- Based on these results, the Phase 3 trial and further development of PF-07265803 will be discontinued. This decision is not based on safety concerns.
- Patients enrolled in the Phase 3 trial will stop study medication and complete any necessary follow-up evaluations. Detailed data from the REALM-DCM study will be presented at future medical meetings to help inform ongoing research.
- The asset was added when Pfizer acquired Array BioPharma for $11.4 billion in 2019, mainly focused on oncology but included a few non-cancer assets, including a Phase 3 drug being tested in a rare cardiovascular disease.
- Pfizer was testing PF-07265803, formerly ARRY-797, in patients with symptomatic dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA).
- LMNA-related DCM involves left ventricular enlargement and/or reduced systolic function. Arrhythmias and conduction system disease also sometimes accompany the rare inherited condition.
- Price Action: PFE shares are down 0.22% at $49.75 during the market session on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!